Acute pulmonary embolism may cause right heart failure due to increased pulmonary vascular resistance and arterial hypoxemia. Effective vasodilator therapy of the pulmonary hypertension is highly needed. Therefore, we investigated the effects of a newly developed effective pulmonary vasodilator, the organic mononitrites of 1,2-propanediol (PDNO), in a rabbit model of acute pulmonary embolism. In anesthetized and ventilated rabbits, systemic and pulmonary hemodynamics, exhaled nitric oxide (NO), plasma nitrite concentration, and blood gases were monitored. First, dose-response experiments with intravenous and left heart ventricle infusions of PDNO and inorganic nitrite were done in naive animals and in pulmonary hypertension induced by a thromboxane A 2 analogue. Second, acute pulmonary embolism was induced and either PDNO or placebo were administered intravenously within 20 minutes and evaluated within 1 hour after pulmonary embolization. PDNO intravenously, in contrast to inorganic nitrite intravenously, increased exhaled NO and counteracted pulmonary hypertension and vasodilated the systemic circulation, dose-dependently, thereby showing efficient NO donation. Pulmonary embolization induced pulmonary hypertension and gas exchange disturbances. PDNO significantly decreased and normalized pulmonary vascular resistance and the right ventricle rate-pressure product, without causing tolerance, with no significant side effects on the systemic circulation, nor on blood-gas values or on methemoglobin formation. In conclusion, PDNO is a NO donor and an efficient vasodilator in the pulmonary circulation. Treatment with this or similar organic nitrites intravenously may be a future option to avoid right heart failure in life-threatening acute pulmonary embolism.
| INTRODUCTION
Acute pulmonary embolism (PE) results in acute pulmonary hypertension, induced by pulmonary vascular macro-or micro-obstruction together with active vasoconstriction, due to released vasoconstrictive mediators and scavenging of nitric oxide (NO) by cell-free hemoglobin. 1, 2 In addition, acute PE severely disturbs ventilation-perfusion matching leading to hypoxemia. 3 Counteraction of the pulmonary hypertension by vasodilators or mediator antagonists could be a treatment strategy in acute PE. Since multiple vasoconstrictive mediators are involved, treatment with mediator antagonists is likely to be only partially successful.
NO is a vasodilator in the pulmonary circulation 4 and we found that the fraction of NO in exhaled gas (FENO) increased in acute PE and that endogenous NO production was protective in two models of experimental PE. 5, 6 The NO donors nitroglycerin and sodium nitroprusside have shown some beneficial effects in animal models of PE, but the vasodilation was more pronounced in the systemic circulation and nitroglycerin may also impair the gas exchange, thereby limiting the applicability of these drugs in acute PE. 7, 8 Furthermore, sildenafil, inorganic nitrite and a nitric oxide-releasing aspirin have shown beneficial effects in animal models of acute PE. [9] [10] [11] [12] [13] In acute PE, inorganic nitrite attenuated the increase in matrix metalloproteinase-9 and had anti-oxidant effects. 10, 11 L-arginine and the NO donor diethylenetriamine/nonoate were inactive in acute PE. 14 The effects of inhaled NO in PE are not conclusive, with modest hemodynamic improvement but only minor or no improvement in blood gases. 15 Still, a recent single-centre phase I trial considered inhaled NO safe in submassive PE and suggested a clinical treatment protocol. 16 NO donors of organic nitrite type are converted to NO in vivo 17, 18 and in contrast to organic nitrates 19 they exhibited little or no tolerance. 20 Ethyl nitrite has been suggested as an inhaled therapeutic but might evoke significant methemoglobin formation. 21 Recently, we synthesized novel organic nitrites and found that the polarity of the individual organic nitrite molecule determined its relative selectivity for vasodilation in the pulmonary and systemic circulations. 18 The two novel organic mononitrites, 2-hydroxy propyl nitrite and 2-hydroxy-1-methylethyl nitrite (henceforth referred to as PDNO, Supplementary Figure S1 for molecular structure) are of particular interest to investigate in experimental acute PE, because this composition exhibited increased vasodilator selectivity toward the pulmonary circulation compared to for example nitroglycerin. 18, 22 In addition, the vasodilatory action of PDNO was devoid of cross tolerance with nitroglycerin in the systemic and pulmonary circulations, indicating bioactivation via another pathway. 22 We hypothesized that PDNO intravenously can counteract the pulmonary hypertension in acute experimental PE, without inducing systemic side effects or gas exchange disturbances, nor methemoglobinemia. To distinguish the effects of the PDNO solution from inorganic nitrite and NO gas, we first performed in vivo dose-response experiments with measurement of FENO, pulmonary and systemic hemodynamics, methemoglobin and plasma nitrite both in naive animals and in animals with pharmacologically induced pulmonary hypertension. To investigate whether fast disappearance of PDNO from the circulation is one mechanism for the relatively larger effects in the pulmonary compared with the systemic circulation, we compared the effects of intravenous and left heart ventricle PDNO infusions.
We show that the NO donor PDNO, in contrast to inorganic nitrite, is a short-lived efficient vasodilator in vivo and that PDNO is effective in counteracting the pulmonary hypertension of acute PE without overt side effects.
| METHODS

| Test systems used
| Animals
Male New Zealand white rabbits (body weight 2.5-3.5 kg, n = 37)
were used, since this animal species has been used previously for investigations of FENO and the pulmonary circulation. 5, 6, 18 The procedures were as humane as possible, and the study was conducted in accordance with the Directive 2010/63/EU on the protection of animals used for scientific purposes. The rabbits were single-housed in plastic-cages in room temperature and had free access to water and standard laboratory rabbit food. They were kept in a 12 hours day and 12 hours night cycle. The experiments were approved by the regional animal ethics committee (Stockholms Norra djurförsök-setiska nämnd, Stockholm, Sweden: Registration numbers N400/03, N148/08 and N178/11). All studies involving animals are reported according to the ARRIVE guidelines for reporting experiments involving animals. immediately after the tracheal cannula. FENO in mixed exhaled gas was measured by chemiluminescence. 6 Mean systemic arterial blood pressure (MAP) and heart rate (HR) were monitored by the AS/3 by a pressure transducer (PX600P) connected to a catheter in the left common carotid artery. In some animals the left carotid catheter was introduced into the left ventricle (position confirmed by pressure monitoring) for intracardiac drug infusions. In these animals, MAP and HR were measured and arterial blood was collected via a catheter in the right femoral artery. In the first and second sets of dose-response experiments the preparation was complete at this point and the animals were allowed a 30-60 minutes interventionfree period.
In experiments with pharmacologically induced pulmonary hypertension (third set of dose-response experiments) and in acute PE, the animals were additionally instrumented and mean pulmonary arterial pressure (mPAP), mean left atrial pressure (LAP), and cardiac output were measured as in Nilsson et al. 18 Material for muscle tissue pulmonary embolization (MPE) was prepared from the right anterior tibial skeletal muscle. 6 After the surgery, the animals were allowed a 30-60 minutes intervention-free period.
A ) was added to the infusate and the infusion rate was 10 mL kg After the experiments, the animals were killed by pulmonary air embolization in general anesthesia.
| Experimental protocols
The operator (author KFN) was not blinded to the interventions due to feasibility reasons.
| Protocol for the exploratory dose-response experiments
In a first set of experiments, rabbits received the following solutions The control group subjected to MPE but saline as drug infusion behaved like the placebo group and data in this control group is not shown. In parallel with blood gases, mixed exhaled gas samples were collected at the outlet of the exhalate mixing chamber and analyzed in the ABL520. 
| Data and statistical analysis
Physiological dead space as a fraction of the tidal volume was calculated with the Bohr equation 24 and was corrected for the dead space of the ventilator system.
Pulmonary ventilation-perfusion characteristics were monitored by measurements of venous admixture, which was calculated by using the classical shunt equation, that is the true shunt as a fraction of total cardiac output. 24 Half-life of inorganic plasma nitrite was determined by applying the data to a one-compartment model using the least squares method (Sigma-Stat, Jandel, San Rafael, CA, USA; supplementary information).
Data are expressed as means ± SEM. For some variables, normalization was employed to control for unwanted sources of variation.
Two-way ANOVA on repeated measures was used with time or dose as one factor and drug solution or infusion site as the other factor.
Tukey test was used as in post-hoc testing. P < 0.05 was considered statistically significant. All statistical tests were performed by using commercial software (SigmaStat v. 3.10.0, Systat Software Inc., San
Jose, CA, USA). The data analysis was not blinded due to feasibility reasons.
| Materials
PDNO consists of the compounds 2-hydroxy propyl nitrite (compound 1 in Supplementary Figure S1 , 63%) and 2-hydroxy-1-methylethyl nitrite (compound 2 in Supplementary Figure S1 , 37%). 18 For preparation of PDNO, NO-saturated saline (Saline + NO) and 1,2-propanediol with inorganic nitrite (PD + nitrite) and without organic nitrite (PD) were prepared as described in supplementary information and Nilsson et al. 18 The solutions were administered to animals (see below) for the determination of biological effects and analyzed either directly in a nitrite reduction system or in HPLC coupled to nitrite reduction to quantify NO gas and inorganic and organic nitrite contents previously described 18, 25 with a few modifications which are described in detail in the supplementary information (Supplementary Figure S2 shows an original recording of the chromatogram and the synchronized nitrite analysis). The contents of inorganic nitrite, organic nitrites, and NO gas are shown in supplementary information and in particular supplementary without NO gas or inorganic nitrite had no effects (data not shown).
| Effects on methemoglobin concentration and blood gases
Methemoglobin increased at larger doses of PDNO, PD + nitrite, and PDNO but remained below 2.0% in all animals ( Figure 1D ). (Table 1) . Other blood-gas values were not affected in infusions with PDNO, PD + nitrite, and Saline + NO (Table 1) .
| Effects on pulmonary and systemic hemodynamics in pharmacologically induced pulmonary hypertension
At baseline both groups showed similar and normal values ( Figure 2 and data not shown). Pulmonary hypertension was induced by intravenous administration of U46619 which increased mPAP, PVR (bỹ 150%), SVR and slightly increased CVP, and decreased cardiac output ( Figure 2 and data not shown) to a similar degree in both groups, whereas MAP, HR, and LAP were not changed (data not shown).
PDNO (n = 4) significantly decreased mPAP, PVR, and SVR and increased cardiac output compared to PD + nitrite (n = 3), which had little or no effects at corresponding doses ( Figure 2 and data not shown). showed that both PDNO and PD + nitrite increased plasma nitrite concentrations but that the biological effects were very different (Figure 1-3) . This was evident when plotting the effects on PVR and SVR by PDNO and PD + nitrite vs the plasma nitrite concentration they caused ( Figure 4) . A similar differentiation between plasma nitrite and effects on FENO, MAP, and HR was observed (data not shown). After stopping the PDNO infusion the methemoglobin started to decrease toward normal values (data not shown) and all animals had methemoglobin <1% during the study period.
| Effects
| Intravenous vs left heart ventricle infusions
| Effects of acute pulmonary embolism
| DISCUSSION
This study showed pulmonary vasodilatory effects of the new organic nitrite NO donor PDNO in pulmonary hypertension of acute PE, without any severe adverse effects. Methemoglobin was <1%, that is well below 2.5% which has been considered safe for inhaled NO, 27 and it was recently shown that infusion of PDNO for more than 6 hours in sheep did not significantly increase the fraction of methemoglobin. 28 The initial dose-response experiments with PDNO and inorganic nitrite showed that PDNO was an efficient vasodilator both in the pulmonary and systemic circulations, and that PDNO released NO as shown by the increase in FENO. In contrast, inorganic nitrite, at the doses used in this study, was a weak systemic vasodilator without capacity of affecting the pulmonary hypertension induced by a thromboxane A 2 analogue (U46619). Both intravenous infusions of PDNO and inorganic nitrite increased the plasma nitrite concentration. By correlating the vasodilator properties of PDNO and inorganic nitrite with the plasma nitrite levels caused by the respective infusion, it can be concluded that the major part of the vasodilatory actions of PDNO was not via increments in plasma inorganic nitrite.
Furthermore, the short half-life of the vasodilation by PDNO (a few minutes) and the large difference between the intravenous and left heart ventricle infusions suggesting fast disappearance of PDNO from the circulation strengthened that the active species was not inorganic nitrite. In contrast, the half-life of inorganic nitrite was estimated to 43 minutes which is in the same range previously determined in rabbits 32 and in humans. 33 Likely, the pulmonary F I G U R E 2 Effects of organic and inorganic nitrite infusions on pulmonary (mean pulmonary arterial pressure, mPAP, panel A; pulmonary vascular resistance, PVR, panel B) and systemic hemodynamics (systemic vascular resistance, SVR, panel C) during induced pulmonary hypertension in anesthetized and ventilated rabbits. The thromboxane A 2 -mimetic U46619 was continuously administered intravenously to induce pulmonary hypertension (increase of pulmonary vascular resistance, PVR, by 100-200%). Thereafter, the organic mononitrites (1,2-propanediol (PDNO), n = 4) or 1,2-propanediol with 20 mmol L −1 inorganic nitrite (PD + nitrite, n = 3) were delivered intravenously in increasing doses. The lower and upper x-axis in each panel show the dose of organic nitrite (for the PDNO) and the total dose of nitrites (organic nitrites + inorganic nitrite) of the infusions, respectively. The circles below zero on the x-axis show baseline values that is before U46619 infusion. * and # indicate a significant difference when comparing the effects of PD + nitrite and PDNO, respectively, at the specific doses with only U46619 infusion (nitrites doses of 0).
§ denotes a significant difference between the two groups at the actual dose. Although the largest doses were not identical in the two groups they were still included for comparison in the analysis The low vasodilatory efficacy of inorganic nitrite in the pulmonary circulation in this study is coherent with studies in rats 34 and newborn lambs. [35] [36] [37] In particular, the classic NO donor sodium nitroprusside was more than 100 times more potent than inorganic nitrite in rats with pulmonary hypertension. 34 Intravenous inorganic nitrite given in large bolus doses at 10-100 μmol kg -1 and 145 μmol kg -1 counteracted the pulmonary hypertension induced by a thromboxane A 2 analogue (U46619) in rats 34 and hypoxic pulmonary vasoconstriction in newborn lambs, respectively. 35 In newborn lambs, nebulized inorganic nitrite at doses of 4.3-43 μmol kg -1 min -1 had pulmonary vasodilatory effects in models of pulmonary hypertension. 36, 37 The nebulized inorganic nitrite in these studies also slightly increased FENO, 36, 37 which might have arisen from the ventilator circuit and not the animal, 36 whereas intravenous infusions of inorganic nitrite did not affect FENO. 35 In contrast, dogs seem to be more sensitive to intravenous inorganic nitrite since inorganic nitrite intra- were needed. Importantly, doses of inorganic nitrite required to acutely lower pulmonary and systemic blood pressures also increased the methemoglobin level. [33] [34] [35] 38, 39 The interaction of inorganic nitrite with hemoglobin in red blood cells provides a convenient explanation for the formation of methemoglobin observed, 38 but the major part of the NO generated from inorganic nitrite in hypoxia arise from other tissues, 40 which might explain the potential protective effects of inorganic nitrite in ischemia-reperfusion injuries. 41 The beneficial effects of NO in acute PE may be several. First, NO act as a vasodilator in the pulmonary circulation, thus § denotes a statistical difference between the two infusion modes at the particular dose of PDNO counteracting the pulmonary hypertension that is due to the release of vasoactive mediators and endothelial dysfunction in the pulmonary vasculature. 2, 42 Pulmonary vasodilation leads to decreased work load on the right heart and thus lowered oxygen demand of the right heart, which is beneficial in conditions associated with hypoxemia. Evidence in this study for such an effect was that PDNO decreased PVR and right ventricular RPP, which is a good estimate of oxygen consumption of the right heart. 43 Second, NO is an important regulator of coronary blood flow to the right ventricle at rest, in global hypoxia (and thus hypoxemia), and in pulmonary hypertension. 43, 44 This effect may be important in a human suffering from acute PE and especially those with risk factors for atherosclerosis where the endothelial NO production in the coronary circulation is diminished. 45, 46 Future indications for the use of organic nitrites, for example PDNO, in acute PE could be as a life-saving treatment, to relieve the work load of the right heart by pulmonary vasodilation, in addition to current conventional and non-conventional treatments: heparin, thrombolysis, embolectomy, or extracorpeal life support. [57] [58] [59] NO donors of the organic nitrite type have been used for more than a century for anginal pain, but their effects have never been investigated in PE as far as the present authors know. We conclude that the new organic nitrite compounds exerted beneficial effects, that is decreased pulmonary vascular resistance and decreased right ventricle pressure product, in experimental acute PE. The organic nitrites used were free from adverse methemoglobin formation, systemic hypotension, disturbed gas exchange, and tolerance development.
Thus, organic nitrites with short half-life emerge as a new tentative life saving treatment in acute PE. The potency of organic nitrite to exert hemodynamic effects is superior to inorganic nitrite and hemodynamic effects of inorganic nitrite in rabbits were associated with methemoglobin formation. This study shows that it is very important to monitor methemoglobin when using inorganic and organic nitrites, as this may be a serious adverse effect. In future studies, the effects of the new organic nitrite should be tested in other relevant clinical conditions associated with pulmonary hypertension. propanediol mononitrites (PDNO). * and # denote a significant difference compared to baseline in the placebo group and in the PDNO group, respectively. § denotes a significant difference between the two groups at the actual time point. n = 6 in each group. CO, cardiac output; TV, tidal volume
